Investigational drug · Phase 2
OPM-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "OPM-101"
First trial start
2025
Sep 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OPM-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "OPM-101" as an intervention, largest first.
- Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1Not yet recruiting
Oncodesign Precision MedicineIndustry
NCT07040436 · 41 participants (planned) · Start Sep 2025 · Primary completion Sep 2027
Drug: OPM-101 · For: Advanced Melanoma
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Melanoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
- BrenetafuspIMC-F106CPhase 32 trials
Immunocore Ltd · Select Advanced Solid Tumors, Advanced Melanoma
- RO7198457Autogene CevumeranPhase 24 trials
Roche (Genentech) · Colorectal Cancer Stage II, Colorectal Cancer Stage III, Adenocarcinoma, Pancreatic Ductal
- T3011Phase 24 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Advanced Solid Tumors, Nonmuscle-invasive Bladder Cancer, Solid Tumor
- LM103 TILsPhase 22 trials
Suzhou BlueHorse Therapeutics Co., Ltd. · Advanced Melanoma, Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.